Corgenix Obtains European Patent for Aspirin Resistance Testing

 

February 27, 2008

February 27, 2008 - Corgenix Medical Corp. received notification of European Patent Office (EPO) approval for technology to which Corgenix holds exclusive worldwide licensing rights.

McMaster University (McMaster) of Hamilton, Ontario, is the owner of the patent covering the aspirin resistance measurement method. Corgenix has licensed this technology from McMaster and is presently developing products to capitalize on the European protected technology. The patented technology is also related to Corgenix� AspirinWorks test kit, which received FDA clearance in 2007.

The EPO patent approval covers the ability to assess a patient�s resistance to the anti-clotting effects of aspirin and also to assess the risk of a cardiovascular event (heart attack or stroke) in patients taking aspirin.

The AspirinWorks test is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which reportedly aids in the qualitative detection of aspirin effect.

For more information: www.corgenix.com